Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 HKD | -3.70% | -16.13% | -32.56% |
10:20am | Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug | MT |
Apr. 17 | Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.56% | 5.69B | B- | ||
+25.02% | 672B | C+ | ||
+24.08% | 550B | B | ||
-6.35% | 351B | C+ | ||
+14.97% | 317B | B- | ||
+6.99% | 292B | C+ | ||
+3.26% | 211B | B+ | ||
+0.78% | 203B | B- | ||
-10.35% | 144B | C+ | ||
-7.60% | 141B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1177 Stock
- Ratings Sino Biopharmaceutical Limited